Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1968 3
2006 3
2007 2
2008 2
2014 1
2015 1
2017 1
2018 4
2019 4
2020 11
2021 9
2022 8
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D; KEYNOTE-826 Investigators. Monk BJ, et al. Among authors: tekin c. J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1. J Clin Oncol. 2023. PMID: 37910822
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: tekin c. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D. Monk BJ, et al. Among authors: tekin c. Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3. Lancet Oncol. 2023. PMID: 36878237 Clinical Trial.
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D. Tewari KS, et al. Among authors: tekin c. JAMA Oncol. 2024 Feb 1;10(2):185-192. doi: 10.1001/jamaoncol.2023.5410. JAMA Oncol. 2024. PMID: 38095881 Clinical Trial.
Global Bandits.
Atan O, Tekin C, van der Schaar M. Atan O, et al. Among authors: tekin c. IEEE Trans Neural Netw Learn Syst. 2018 Dec;29(12):5798-5811. doi: 10.1109/TNNLS.2018.2818742. Epub 2018 Apr 12. IEEE Trans Neural Netw Learn Syst. 2018. PMID: 29993936
Reply to P.-H. Luo et al.
Monk BJ, Colombo N, Tewari KS, Tekin C, Keefe SM, Lorusso D. Monk BJ, et al. Among authors: tekin c. J Clin Oncol. 2024 May 1;42(13):1596-1598. doi: 10.1200/JCO.24.00077. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452314 No abstract available.
59 results